Resources

When managing type 2 diabetes, should clinicians still begin with one medication and wait for treatment failure before intensifying therapy? Increasingly, evidence suggests that early combination therapy in type 2 diabetes may provide better durability, faster glycemic control, and improved cardiovascular and kidney outcomes in high-risk patients. While metformin monotherapy …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …

Dermatologic reactions linked to GLP-1 therapy are gaining attention as the use of glucagon-like peptide-1 receptor agonists continues to expand in diabetes and obesity care. While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide …

As GLP-1 receptor agonists become a mainstay in type 2 diabetes and obesity care, more patients are pairing medication with structured training programs. However, how do GLP-1 medications actually influence metabolism during exercise? Questions about fueling, endurance, fatigue, and muscle adaptation are becoming more common in clinical practice. The relationship …

Using GLP-1 therapy for lean type 2 diabetes challenges a long-standing assumption in diabetes care: that glucagon-like peptide-1 receptor agonists are primarily for patients with obesity. But what if body mass index is not the right guide for treatment decisions? Lean individuals with type 2 diabetes often exhibit insulin resistance, …

Can a medication designed to lower blood sugar also influence how the body handles iron? As research into the link between GLP-1 therapy and iron metabolism grows, scientists are beginning to explore how incretin signaling may intersect with inflammation, anemia, and iron regulation pathways. While GLP-1 receptor agonists are widely …

The expanding use of GLP-1 receptor agonists for type 2 diabetes and obesity has transformed metabolic care. However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety. Rapid weight loss and altered bile composition during treatment may …

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. …

In 2026, diabetic retinopathy screening is entering a new era driven by artificial intelligence, tele-retinal imaging, and smarter integration into primary care workflows. Despite improved glucose monitoring and widespread use of CGM systems, diabetic retinopathy remains a leading cause of preventable blindness in adults with diabetes. So how can clinicians …